Heterodimerization of AML1/ETO with CBFβ is Required for Leukemogenesis but Not for Myeloproliferation

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2017 Apr 1

PMID 28360416

Citations 12

Authors

V N Thiel

B D Giaimo

P Schwarz

K Soller

V Vas

M Bartkuhn

T J Blatte

K Dohner

L Bullinger

T Borggrefe

H Geiger

F Oswald

Affiliations

Soon will be listed here.

Abstract

The AML1/Runx1 transcription factor and its heterodimerization partner CBFβ are essential regulators of myeloid differentiation. The chromosomal translocation t(8;21), fusing the DNA binding domain of AML1 to the corepressor eight-twenty-one (ETO), is frequently associated with acute myeloid leukemia and generates the AML1/ETO (AE) fusion protein. AE represses target genes usually activated by AML1 and also affects the endogenous repressive function of ETO at Notch target genes. In order to analyze the contribution of CBFβ in AE-mediated leukemogenesis and deregulation of Notch target genes, we introduced two point mutations in a leukemia-initiating version of AE in mice, called AE9a, that disrupt the AML1/CBFβ interaction (AE9aNT). We report that the AE9a/CBFβ interaction is not required for the AE9a-mediated aberrant expression of AML1 target genes, while upregulation/derepression of Notch target genes does require the interaction with CBFβ. Using retroviral transduction to express AE9a in murine adult bone marrow-derived hematopoietic progenitors, we observed that both AE9a and AE9aNT lead to increased myeloproliferation in vivo. However, both development of leukemia and long-term replating capacity are only observed with AE9a but not with AE9aNT. Thus, deregulation of both AML1 and Notch target genes is required for the development of AE9a-driven leukemia.

Citing Articles

Single-cell RNA sequencing of a new transgenic t(8;21) preleukemia mouse model reveals regulatory networks promoting leukemic transformation.

Yan M, Liu M, Davis A, Stoner S, Zhang D Leukemia. 2023; 38(1):31-44.

PMID: 37838757 PMC: 10776403. DOI: 10.1038/s41375-023-02063-z.

The RUNX Family of Proteins, DNA Repair, and Cancer.

Krishnan V Cells. 2023; 12(8).

PMID: 37190015 PMC: 10136874. DOI: 10.3390/cells12081106.

George B, Yohannan B, Mohlere V, Gonzalez A Int J Hematol Oncol. 2023; 12(1):IJH43.

PMID: 36874378 PMC: 9979104. DOI: 10.2217/ijh-2022-0004.

Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia.

Issa H, Swart L, Rasouli M, Ashtiani M, Nakjang S, Jyotsana N Leukemia. 2023; 37(4):820-834.

PMID: 36823395 PMC: 10079536. DOI: 10.1038/s41375-023-01854-8.

Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives.

Bouligny I, Maher K, Grant S Blood Rev. 2022; 57:100996.

PMID: 35989139 PMC: 10693933. DOI: 10.1016/j.blre.2022.100996.

References

Oswald F, Rodriguez P, Giaimo B, Antonello Z, Mira L, Mittler G . A phospho-dependent mechanism involving NCoR and KMT2D controls a permissive chromatin state at Notch target genes. Nucleic Acids Res. 2016; 44(10):4703-20. PMC: 4889922. DOI: 10.1093/nar/gkw105. View

Martens J, Mandoli A, Simmer F, Wierenga B, Saeed S, Singh A . ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood. 2012; 120(19):4038-48. PMC: 3496958. DOI: 10.1182/blood-2012-05-429050. View

Gilliland D . Targeted therapies in myeloid leukemias. Ann Hematol. 2004; 83 Suppl 1:S75-6. DOI: 10.1007/s00277-004-0850-2. View

Kozu T, Miyoshi H, Shimizu K, Maseki N, Kaneko Y, Asou H . Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood. 1993; 82(4):1270-6. View

Lobry C, Ntziachristos P, Ndiaye-Lobry D, Oh P, Cimmino L, Zhu N . Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med. 2013; 210(2):301-19. PMC: 3570103. DOI: 10.1084/jem.20121484. View

Meyers S, Lenny N, Hiebert S . The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol. 1995; 15(4):1974-82. PMC: 230424. DOI: 10.1128/MCB.15.4.1974. View

Frank R, Zhang J, Uchida H, Meyers S, Hiebert S, Nimer S . The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene. 1995; 11(12):2667-74. View

Ahn E, Yan M, Malakhova O, Lo M, Boyapati A, Ommen H . Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis. Proc Natl Acad Sci U S A. 2008; 105(44):17103-8. PMC: 2579385. DOI: 10.1073/pnas.0802696105. View

Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, Buonamici S . A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 2011; 473(7346):230-3. PMC: 3093658. DOI: 10.1038/nature09999. View

10.

Jiao B, Wu C, Liang Y, Chen H, Xiong S, Chen B . AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. Leukemia. 2009; 23(9):1598-604. DOI: 10.1038/leu.2009.104. View

11.

Salat D, Liefke R, Wiedenmann J, Borggrefe T, Oswald F . ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes. Mol Cell Biol. 2008; 28(10):3502-12. PMC: 2423149. DOI: 10.1128/MCB.01966-07. View

12.

Higuchi M, OBrien D, Kumaravelu P, Lenny N, Downing J . Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell. 2002; 1(1):63-74. DOI: 10.1016/s1535-6108(02)00016-8. View

13.

Lowenberg B, Downing J, Burnett A . Acute myeloid leukemia. N Engl J Med. 1999; 341(14):1051-62. DOI: 10.1056/NEJM199909303411407. View

14.

Giaimo B, Oswald F, Borggrefe T . Dynamic chromatin regulation at Notch target genes. Transcription. 2016; 8(1):61-66. PMC: 5279717. DOI: 10.1080/21541264.2016.1265702. View

15.

Morohoshi F, Mitani S, Mitsuhashi N, Kitabayashi I, Takahashi E, Suzuki M . Structure and expression pattern of a human MTG8/ETO family gene, MTGR1. Gene. 2000; 241(2):287-95. DOI: 10.1016/s0378-1119(99)00481-3. View

16.

Wacker S, Alvarado C, von Wichert G, Knippschild U, Wiedenmann J, Clauss K . RITA, a novel modulator of Notch signalling, acts via nuclear export of RBP-J. EMBO J. 2010; 30(1):43-56. PMC: 3020113. DOI: 10.1038/emboj.2010.289. View

17.

Gu T, Goetz T, Graves B, Speck N . Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1). Mol Cell Biol. 1999; 20(1):91-103. PMC: 85059. DOI: 10.1128/MCB.20.1.91-103.2000. View

18.

Feinstein P, Kornfeld K, Hogness D, Mann R . Identification of homeotic target genes in Drosophila melanogaster including nervy, a proto-oncogene homologue. Genetics. 1995; 140(2):573-86. PMC: 1206636. DOI: 10.1093/genetics/140.2.573. View

19.

Weng A, Ferrando A, Lee W, Morris 4th J, Silverman L, Sanchez-Irizarry C . Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004; 306(5694):269-71. DOI: 10.1126/science.1102160. View

20.

Borggrefe T, Oswald F . The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell Mol Life Sci. 2009; 66(10):1631-46. PMC: 11115614. DOI: 10.1007/s00018-009-8668-7. View